“For patients with a prior ICM-induced hypersensitivity reaction, healthcare providers must balance the benefit of ICM reuse against the risk of a repeat reaction,” authors of a new meta-analysis published in Radiology said.

On July 18 Fresenius Kabi announced that they are rolling out a line of generic contrast media products, starting immediately with Iodixanol Injection USP. 

Per Bayer’s communications, the contrast agent is manufactured at the same site in Berlin, Germany as the Ultravist that is intended for U.S. markets, but due to its intended distribution abroad it lacks current FDA-approved labeling. 

GE previously indicated that the iodinated contrast shortage would resolve by the end of June.

Beyond readmission, 32.9% of patients with increased pancreatic necrosis volumes required additional invasive interventions.

Such assessments could “decrease existing diagnosis gaps,” according to a new study published in Academic Radiology. 

According to a new SCAI statement, the FDA's recommendation would result in "far-reaching consequences" across multiple specialties. 

Members who signed the letter were particularly critical of the fact that the shortage is a result of COVID lockdowns in China, stating that this crisis brings to light “the urgent need to establish an outbound investment review process to ensure that critical capabilities are not being offshored ..."